Form D · Pharmaceuticals
NuSirt Sciences Inc.
Nashville, TN · CIK 0001642239
Offering snapshot reported Dec 1, 2016 · SEC filing
- Reported sold
- $2M Offering amount: $2M
- Investors reported
- 29 Form D · investor count
- Minimum accepted
- $4.99K Reported outside-investor minimum
- First sale
- Nov 22, 2016 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 1, 2016 | Initial | $1,999,997 | No comparison | 29 | SEC filing |
| Oct 13, 2015 | Initial | $4,000,071 | No comparison | 28 | SEC filing |
| May 14, 2015 | Initial | $2,070,000 | No comparison | 26 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-275493
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| N/A | None |
Source: Form D, filed Dec 1, 2016. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Vaughn Bryson | Director |
| Barbara Cannon | Executive |
| Joseph C. Cook, Jr. | Director, Executive |
| Brian Laden | Director |
| Eric Satz | Director |
| Michael Zemel | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
3835 Cleghorn Avenue Suite 200
Nashville, TN, 37215
Nashville, TN, 37215